Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ≥18 to ≤80 years at time of study~2. Status post PCI with stent implantation requiring antiplatelet therapy~3. Willingness to comply with all study-related procedures~Exclusion Criteria:~1. Pending imminent surgery placing patients at increased risk for bleeding with prasugrel or ticagrelor.~2. History of intracranial hemorrhage, TIA, and stroke~3. Active bleeding~4. Need for long-term anticoagulation (i.e. warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, or lovenox).~5. Current or prior (within the past four weeks) treatment with voraxapar (Zontivity).~6. Severe renal or hepatic impairment~7. Treating physician does not want subject to participate~8. Drug allergy to clopidogrel, prasugrel or ticagrelor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYP2C19 Genotype guided (Type: EXPERIMENTAL): Prospective CYP2C19 genotyping to decide antiplatelet therapy.
- Control group (Type: NO_INTERVENTION): Antiplatelet therapy will be decided based on usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).